U.S. markets open in 4 hours 23 minutes

Reneo Pharmaceuticals, Inc. (RPHM)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
7.98+0.22 (+2.84%)
At close: 4:00PM EDT
Full screen
Loading interactive chart...
  • GlobeNewswire

    Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences

    IRVINE, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that management will be participating in five investor conferences during the month of September. Details for the upcoming conferences are as follows: Conference: Citi 16th Annual BioPharma ConferenceDate: September 8-10, 2021Form

  • GlobeNewswire

    Reneo Pharmaceuticals Reports Second Quarter 2021 Financial Results

    First patient dosed in STRIDE study of REN001 in primary mitochondrial myopathiesIRVINE, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic, mitochondrial diseases, today reported financial results for the quarter ended June 30, 2021 and provided an update on its clinical programs. “The second quarter of 2021 was highly productive

  • GlobeNewswire

    Reneo Pharmaceuticals Announces First Patient Dosed in the STRIDE Study

    IRVINE, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the first patient has been dosed in the STRIDE study. The trial is designed to evaluate the efficacy and safety of REN001 for the treatment of patients with primary mitochondrial myopathies (PMM). STRIDE is a global, double-blin